沃華醫藥(002107.SZ):半年度淨利潤預增233.89%-378.27%
格隆匯7月9日丨沃華醫藥(002107.SZ)公佈2025年半年度業績預吿,1-6月公司實現歸屬於上市公司股東的淨利潤盈利3,700.00萬元–5,300.00萬元,比上年同期上升233.89%–378.27%;扣除非經常性損益後的淨利潤盈利3,420.00萬元–4,850.00萬元,比上年同期上升247.96%-393.45%;基本每股收益盈利0.0641元/股–0.0918元/股。
報吿期內,公司逐漸適應市場環境的變化,嘗試各種營銷模式的協同,調整市場佈局,實現營收同比上升。成本控制方面,部分主要原材料採購成本降低,疊加“降本增效”措施的持續推行,成本費用有效壓縮,經營利潤顯著提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.